Search papers, labs, and topics across Lattice.
5Division of Breast Oncology, Dana Farber Cancer Institute, Boston, MA
1
0
0
0
This study will determine if enzalutamide, with or without mifepristone, improves progression-free survival compared to standard chemotherapy in patients with AR+ metastatic triple-negative or estrogen receptor-low breast cancer.